Page last updated: 2024-11-05

benzobarbital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzobarbital: for drug therapy of epilepsy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12938
CHEMBL ID1338506
SCHEMBL ID2109448
MeSH IDM0043743

Synonyms (46)

Synonym
744-80-9
AC-19990
STL301913
5-ethyl-5-phenyl-1-(phenylcarbonyl)pyrimidine-2,4,6(1h,3h,5h)-trione
OPREA1_179037
barbituric acid, 1-benzoyl-5-ethyl-5-phenyl-
benzonalum
benzobarbital
2,4,6(1h,3h,5h)-pyrimidinetrione, 1-benzoyl-5-ethyl-5-phenyl-
benzoylluminal
benzobarbitalum [inn-latin]
5-ethyl-1-benzoyl-5-phenylbarbituric acid
brn 0627140
1-benzoyl-5-ethyl-5-phenylbarbituric acid
benzobarbital [inn]
benzoyluminal
1-benzoyl-5-ethyl-5-phenyl-2,4,6-trioxohexahydropyrimidine
benzonal
benzoylphenobarbital
NCGC00160414-01
1-benzoyl-5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
A838147
5-ethyl-5-phenyl-1-(phenylcarbonyl)-1,3-diazinane-2,4,6-trione
benzobarbital:1-benzoyl-5-ethyl-5-phenyl barbitoric acid
dtxsid1046138 ,
dtxcid9026138
cas-744-80-9
tox21_111797
CHEMBL1338506
unii-ynj78bd0ah
ynj78bd0ah ,
5-24-09-00293 (beilstein handbook reference)
benzobarbitalum
AKOS015896461
benzobarbital [who-dd]
benzobarbital [mart.]
1-benzoyl-5-ethyl-5-phenylpyrimidine-2,4,6(1h,3h,5h)-trione
J-504234
SCHEMBL2109448
QMOWPJIFTHVQMB-UHFFFAOYSA-N
sr-01000212063
SR-01000212063-1
1-benzoyl-5-ethyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione
Q4083796
AS-14647
E79243

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Administration of phenobarbital, benzonal and benzobamil in a dose of 1/20 of LD50 to rats was shown to be followed by phase changes in the system of microsomal oxidation of the liver--activation in the first days after administration with the subsequent (in 1-3 months) decrease of the activity."( [Effect of anticonvulsant agents, inducers of microsomal oxidation, on the B-link of immunity and on the natural cytotoxicity of lymphoid organ cells in rats].
Cherevko, NA; Galenko, OA; Novozheeva, TP; Potapova, GV; Saratikov, AS,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters of this metabolite (PB) were determined in guinea-pigs, and their identity with the pharmacokinetic parameters of PB as the parent drug was confirmed."( Use of normal-phase microcolumn high-performance liquid chromatography for the study of hydrolytic stability, metabolic profiling and pharmacokinetics of an antiepileptic drug, benzonal.
Chankvetadze, BG; Okujava, VM; Rogava, MM; Rukhadze, MD; Tkesheliadze, NB, 1991
)
0.28
"Major pharmacokinetic parameters of the Soviet anticonvulsive drug benzobarbital used with different regimens of administration (single and prolonged) are described."( [Pharmacokinetic aspects of anticonvulsant therapy with benzonal].
Antadze, ZI; Chanvetadze, BG; Chkhenkeli, SI; Okudzhava, VM; Rukhadze, MD, 1988
)
0.51

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The most common of these causes include malpractice of the dosage build-up in the absence of the clinical effect, polytherapy--not infrequently with drugs of the same chemical group, and insufficient attention to the potentiating drug interaction."( [Phenomenon of "paradoxical poisoning" during antiepileptic therapy].
Geladze, TSh, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency28.18380.01237.983543.2770AID1346984
pregnane X nuclear receptorHomo sapiens (human)Potency28.18380.005428.02631,258.9301AID1346985
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.49150.000323.4451159.6830AID743065
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency112.20200.010323.856763.0957AID2662
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency9.07430.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (52.38)18.7374
1990's13 (30.95)18.2507
2000's3 (7.14)29.6817
2010's3 (7.14)24.3611
2020's1 (2.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.17 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (4.48%)5.53%
Reviews3 (4.48%)6.00%
Case Studies2 (2.99%)4.05%
Observational0 (0.00%)0.25%
Other59 (88.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]